Listen: Behind Apple's Decision to Make iPhones in India
🎧 Listen to WSJ's Tech News Briefing podcast
📰 Or read Tripti's deep dive here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
SendCutSend Doubles Down on Business Tools as More Teams Tap Into Enterprise Features
Company Joins Inc. 5000 List for Third Straight Year RENO, Nev., Aug. 12, 2025 /PRNewswire/ -- As more companies turn to fast, flexible American manufacturing, SendCutSend is seeing growing demand for business tools built for engineering teams, purchasing departments, and production managers. The company offers features like multi-user organization accounts, net-30 payment terms, dedicated account representatives, and built-in design for manufacturability (DFM) checks, streamlining the way businesses order and scale custom parts. These business features, which have been part of SendCutSend's platform for several years, are seeing record adoption across industries. That growth has helped SendCutSend earn #511 on the Inc. 5000 list of the fastest-growing private companies in the U.S. for the third year in a row. "These aren't brand-new tools, they've just become a bigger part of how companies are working with us," said Jim Belosic, CEO and co-founder of SendCutSend. "We're building for speed and simplicity. And the more we can take off our customers' plates, the better." SendCutSend works with thousands of companies, including more than half of the Fortune 500. Its platform supports everything from prototyping to large production runs, with no order minimums and more than 170 materials and finishes available. Most parts ship in 2–3 business days, with rush production now available on select services. Every file uploaded to SendCutSend is automatically checked by the DFM engine, which flags potential manufacturing issues, before a part moves to production. This helps reduce errors and cuts down on delays, especially for teams working through design iterations or repeat runs. SendCutSend was founded in 2018 and operates production facilities in Nevada, Kentucky, and Texas. The company has shipped more than 50 million parts to over 300,000 customers. For more information, visit About SendCutSendSendCutSend is an on-demand, custom sheet metal manufacturing company with facilities in Reno, Nev., Paris, Ky., and Arlington, Texas serving the United States and Canada. Founded by two software engineers frustrated by the lack of access to commercial manufacturing, SendCutSend bridges the gap between quality, speed, affordability and convenience in the manufacturing industry. From its humble beginnings in a garage to landing on the Inc 5000 and Deloitte Technology Fast 500, SendCutSend is proud to now call 59% of the companies in the Fortune 500 customers. SendCutSend offers laser cutting and finishing services for everything from one-off prototypes to sale/assembly ready parts at scale shipped in as little as two days with no minimum quantities. For more information visit or follow on Instagram and YouTube. View original content to download multimedia: SOURCE SendCutSend Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. Brinsupri is the first and only FDA-approved treatment for NCFB, a chronic lung condition characterized by permanently widened and damaged airways (bronchi), leading to persistent mucus production, recurrent infections, and difficulty breathing. There are approximately 500,000 people in the U.S. diagnosed with NCFB. The approval is based on data from the Phase 3 ASPEN and Phase 2 WILLOW ASPEN, patients taking Brinsupri 10 mg or 25 mg had a 21.1% and 19.4% reduction in the annual rate of exacerbations, respectively, as compared to placebo. Both dosage strengths of Brinsupri also met several exacerbation-related secondary endpoints, including significantly prolonging the time to first exacerbation and significantly increasing the proportion of patients remaining exacerbation-free over the treatment period. Patients who received Brinsupri 25 mg experienced a statistically significantly less decline in lung function, as measured by forced expiratory volume in one second (FEV₁) after using a bronchodilator, at week 52. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions in WILLOW. In parallel, applications for brensocatib with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have been accepted, and the company plans to file in Japan in 2025. Commercial launches are anticipated in 2026, pending approval in each territory. Price Action: INSM stock is up 6.20% at $119.89 at the last check on Tuesday. Read Next:Photo: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? INSMED (INSM): Free Stock Analysis Report This article FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
28 minutes ago
- Bloomberg
Apple, Tesla Investor Reacts to Musk's App Store Claims
Laffer Tengler Investments CEO and CIO Nancy Tengler says she doesn't think Elon Musk's accusations that Apple is favoring OpenAI will 'end' the App Store. She talks about her outlook on Apple, Tesla and chip stocks with Caroline Hyde and Ed Ludlow on 'Bloomberg Tech.' (Source: Bloomberg)
